Drilldown: Medicines
Use the filters below to narrow your results.
generic:
Agomelatine (1) ·
Amoxapine (1) ·
Cholecalciferol (vitamin D3) (1) ·
Clomipramine (1) ·
Desipramine (1) ·
Duloxetine (1) ·
Ergocalciferol (vitamin D2) (1) ·
Imipramine (1) ·
Isocarboxazid (1) ·
Levomilnacipran (1) ·
Maprotiline (1) ·
Milnacipran (1) ·
Moclobemide (1) ·
Nefazodone (1) ·
Phenelzine (1) ·
Protriptyline (1) ·
Reboxetine (1) ·
Sertraline (1) ·
Tianeptine (1) ·
Tranylcypromine (1) ·
Trimipramine (1) ·
Vitamin E (α-tocopherol; mixed natural and synthetic forms) (1)
brand:
None (1) ·
Anafranil (1) ·
Aurorix (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Drisdol, Calcidol; also many OTC preparations (1) ·
Edronax (1) ·
Fetzima (1) ·
Generic; many OTC formulations (1) ·
Ludiomil (1) ·
Many OTC; Rx 50,000 IU also available (1) ·
Marplan (1) ·
Nardil (1) ·
Norpramin (1) ·
Parnate (1) ·
Savella (1) ·
Serzone (1) ·
Stablon (1) ·
Surmontil (1) ·
Tofranil (1) ·
Valdoxan (1) ·
Vivactil (1) ·
Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
None (1) ·
Irreversible non-selective MAO inhibitor (3) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Reversible inhibitor of MAO-A (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1) ·
'"`UNIQ--vote-0000032A-QINU`"' D3 (cholecalciferol) is more potent at raising serum 25(OH)D per dose; D2 remains widely prescribed in the US Rx 50,000 IU formulation'"`UNIQ--ref-0000032B-QINU`"'. (1) ·
'"`UNIQ--vote-0000042C-QINU`"' D3 is more potent than D2 at raising and sustaining serum 25(OH)D per dose, and is the more common OTC formulation; D2 remains the dominant Rx 50,000 IU formulation in the US for historical reasons. (1)
uses:
None (18) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
'"`UNIQ--vote-0000032C-QINU`"', '"`UNIQ--vote-0000032D-QINU`"', '"`UNIQ--vote-0000032E-QINU`"', '"`UNIQ--vote-0000032F-QINU`"' (1) ·
'"`UNIQ--vote-0000042D-QINU`"', '"`UNIQ--vote-0000042E-QINU`"', '"`UNIQ--vote-0000042F-QINU`"', '"`UNIQ--vote-00000430-QINU`"' (1) ·
'"`UNIQ--vote-000012CE-QINU`"', '"`UNIQ--vote-000012CF-QINU`"', '"`UNIQ--vote-000012D0-QINU`"' (1)
starting dose:
None (18) ·
25 mg (1) ·
Deficiency: 50,000 IU PO weekly for 8-12 weeks, then maintenance 800-2,000 IU/day; maintenance OTC dosing typically 800-2,000 IU/d (1) ·
Maintenance 800-2,000 IU PO daily; deficiency replacement 50,000 IU PO weekly for 8-12 weeks then maintenance, or equivalent daily dosing 5,000-10,000 IU/d (1) ·
Replacement: 15-30 mg (22.5-45 IU) daily; NASH: 800 IU daily; AREDS-2: 400 IU daily (in combination formula) (1)
preparations:
None (18) ·
100, 200, 400 IU softgels and capsules; many proprietary OTC blends; combined formulations (AREDS-2) (1) ·
25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) ·
50,000 IU capsules (Rx); 8,000 IU/mL oral solution (Rx); 400-5,000 IU OTC tablets and softgels (1) ·
OTC 400, 1,000, 2,000, 5,000 IU softgels and tablets; Rx 50,000 IU capsules; liquid drops 400-2,000 IU/drop (1)
fda max:
routes:
onset:
None (17) ·
Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) ·
Days to weeks for tissue saturation (1) ·
Days to weeks to raise 25(OH)D; clinical effect on bone over months (1) ·
Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) ·
Weeks to raise 25(OH)D into reference range (1)
duration:
halflife:
None (17) ·
~12 hours (1) ·
~24 hours (parent); ~15 days (25(OH)D); 25(OH)D stores persist for months'"`UNIQ--ref-00000330-QINU`"' (1) ·
~24 hours (parent); ~15 days (25(OH)D); tissue stores months (1) ·
~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) ·
~3-4 days plasma; adipose tissue stores last months (1)
bioavailability:
None (17) ·
Absolute bioavailability not precisely characterized; food modestly increases exposure (1) ·
High with fat-containing meal; reduced in malabsorption (1) ·
~50% (highly variable) (1) ·
~75% (oral; absorption improved with fat-containing meal) (1) ·
~75% (oral; fat-soluble, absorption requires intact biliary/lipid digestion)'"`UNIQ--ref-00000331-QINU`"' (1)
pregnancy:
None (17) ·
Category C (1) ·
Category C'"`UNIQ--ref-0000008F-QINU`"' (1) ·
Safe at replacement doses; deficiency is itself a risk in pregnancy and lactation.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Safe at replacement doses; high-dose use generally avoided.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 22 results in range #1 to #22.